Home

The Korea Herald

Latest news

Most Popular

  1. 1

    [AtoZ into Korean mind] Humor in Korea: Navigating the line between what's funny and not

    [AtoZ into Korean mind] Humor in Korea: Navigating the line between what's funny and not
  2. 2

    Yoon seeks rebound, taps 5-term lawmaker as chief of staff

    Yoon seeks rebound, taps 5-term lawmaker as chief of staff
  3. 3

    [Exclusive] Korean military set to ban iPhones over 'security' concerns

    [Exclusive] Korean military set to ban iPhones over 'security' concerns
  4. 4

    Medical standoff deepens as doctors reject new med school plan, talks

    Medical standoff deepens as doctors reject new med school plan, talks
  5. 5

    [Herald Interview] Why Toss invited hackers to penetrate its system

    [Herald Interview] Why Toss invited hackers to penetrate its system
  1. 6

    [Graphic News] 77% of young Koreans still financially dependent

    [Graphic News] 77% of young Koreans still financially dependent
  2. 7

    Korean, Romanian leaders discuss defense tech, nuclear energy

    Korean, Romanian leaders discuss defense tech, nuclear energy
  3. 8

    S. Korean envoys convene to navigate strategy amid Middle East tensions

    S. Korean envoys convene to navigate strategy amid Middle East tensions
  4. 9

    North Korea fires several short-range ballistic missiles into sea: JCS

    North Korea fires several short-range ballistic missiles into sea: JCS
  5. 10

    Samsung, SK hynix investors dump shares on Nvidia crash

    Samsung, SK hynix investors dump shares on Nvidia crash
피터빈트

Celltrion aims to commercialize Herzuma in Japan

By Shim Woo-hyun

Published : April 12, 2017 - 14:36

    • Link copied

Celltrion, a South Korean pharmaceutical company developing biosimilars, submitted a request to the Japanese Ministry of Health, Labor and Welfare for approval to sell Herzuma, the company spokesperson said Wednesday.
(Park Hyun-koo/The Korea Herald) (Park Hyun-koo/The Korea Herald)
Herzuma, also known as CT-P6, references the blockbuster breast cancer drug Herceptin by Genentech, and is used for treatment of metastatic breast cancer and early stage breast cancer.

Partnering with Japanese pharma firm Nippon Kayaku, Celltrion is aiming to introduce Herzuma to the Japanese drug market in 2018. The market size of the original drug in Japan is estimated to be around 450 billion won ($393 million).

Celltrion has been commercializing Remsima, the company’s biosimilar drug for rheumatoid arthritis, through Nippon Kayaku since November 2014. Nippon Kayaku currently has marketing rights for both Remsima and Herzuma in Japan.

By Shim Woo-hyun (ws@heraldcorp.com)

More from Headlines